S&P 500   3,770.53 (+2.50%)
DOW   30,155.66 (+2.25%)
QQQ   280.34 (+2.49%)
AAPL   144.85 (+1.68%)
MSFT   247.47 (+2.80%)
META   140.02 (+1.02%)
GOOGL   101.09 (+2.48%)
AMZN   120.99 (+4.41%)
TSLA   244.93 (+1.04%)
NVDA   129.98 (+3.88%)
NIO   16.58 (+7.04%)
BABA   83.67 (+4.00%)
AMD   67.57 (+2.21%)
T   16.00 (+0.63%)
MU   54.04 (+4.49%)
CGC   3.11 (+6.87%)
F   12.21 (+6.45%)
GE   66.62 (+4.75%)
DIS   100.57 (+3.54%)
AMC   7.52 (+9.30%)
PYPL   91.77 (+5.26%)
PFE   44.29 (+0.34%)
NFLX   238.01 (-0.43%)
S&P 500   3,770.53 (+2.50%)
DOW   30,155.66 (+2.25%)
QQQ   280.34 (+2.49%)
AAPL   144.85 (+1.68%)
MSFT   247.47 (+2.80%)
META   140.02 (+1.02%)
GOOGL   101.09 (+2.48%)
AMZN   120.99 (+4.41%)
TSLA   244.93 (+1.04%)
NVDA   129.98 (+3.88%)
NIO   16.58 (+7.04%)
BABA   83.67 (+4.00%)
AMD   67.57 (+2.21%)
T   16.00 (+0.63%)
MU   54.04 (+4.49%)
CGC   3.11 (+6.87%)
F   12.21 (+6.45%)
GE   66.62 (+4.75%)
DIS   100.57 (+3.54%)
AMC   7.52 (+9.30%)
PYPL   91.77 (+5.26%)
PFE   44.29 (+0.34%)
NFLX   238.01 (-0.43%)
S&P 500   3,770.53 (+2.50%)
DOW   30,155.66 (+2.25%)
QQQ   280.34 (+2.49%)
AAPL   144.85 (+1.68%)
MSFT   247.47 (+2.80%)
META   140.02 (+1.02%)
GOOGL   101.09 (+2.48%)
AMZN   120.99 (+4.41%)
TSLA   244.93 (+1.04%)
NVDA   129.98 (+3.88%)
NIO   16.58 (+7.04%)
BABA   83.67 (+4.00%)
AMD   67.57 (+2.21%)
T   16.00 (+0.63%)
MU   54.04 (+4.49%)
CGC   3.11 (+6.87%)
F   12.21 (+6.45%)
GE   66.62 (+4.75%)
DIS   100.57 (+3.54%)
AMC   7.52 (+9.30%)
PYPL   91.77 (+5.26%)
PFE   44.29 (+0.34%)
NFLX   238.01 (-0.43%)
S&P 500   3,770.53 (+2.50%)
DOW   30,155.66 (+2.25%)
QQQ   280.34 (+2.49%)
AAPL   144.85 (+1.68%)
MSFT   247.47 (+2.80%)
META   140.02 (+1.02%)
GOOGL   101.09 (+2.48%)
AMZN   120.99 (+4.41%)
TSLA   244.93 (+1.04%)
NVDA   129.98 (+3.88%)
NIO   16.58 (+7.04%)
BABA   83.67 (+4.00%)
AMD   67.57 (+2.21%)
T   16.00 (+0.63%)
MU   54.04 (+4.49%)
CGC   3.11 (+6.87%)
F   12.21 (+6.45%)
GE   66.62 (+4.75%)
DIS   100.57 (+3.54%)
AMC   7.52 (+9.30%)
PYPL   91.77 (+5.26%)
PFE   44.29 (+0.34%)
NFLX   238.01 (-0.43%)
NASDAQ:RIGL

Rigel Pharmaceuticals - RIGL Earnings Date, Estimates & Call Transcripts

$1.18
0.00 (0.00%)
(As of 10/4/2022 01:30 PM ET)
Add
Compare
Today's Range
$1.18
$1.25
50-Day Range
$1.10
$1.72
52-Week Range
$0.64
$3.62
Volume
48,401 shs
Average Volume
4.43 million shs
Market Capitalization
$203.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.96

Earnings Summary

Upcoming
Earnings Date
Nov. 1Estimated
Actual EPS
(Aug. 2)
-$0.08 Beat By $0.04
Consensus EPS
(Aug. 2)
-$0.12
Last Year's Q3 EPS
(8/3/2021)
-$0.08
Skip Charts & View Estimated and Actual Earnings Data

RIGL Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RIGL Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Rigel Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20223($0.13)($0.11)($0.12) 
Q2 20223($0.14)($0.11)($0.12) 
Q3 20223($0.14)($0.11)($0.13) 
Q4 20223($0.15)($0.11)($0.13) 
FY 202212($0.56)($0.44)($0.50) 
Q1 20231($0.11)($0.11)($0.11) 
Q2 20231($0.11)($0.11)($0.11) 
Q3 20231($0.10)($0.10)($0.10) 
Q4 20231($0.10)($0.10)($0.10) 
FY 20234($0.42)($0.42) ($0.42)

RIGL Earnings Date and Information

Rigel Pharmaceuticals last issued its earnings data on August 2nd, 2022. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The business earned $29.82 million during the quarter, compared to analysts' expectations of $23.56 million. Rigel Pharmaceuticals has generated ($0.49) earnings per share over the last year (($0.49) diluted earnings per share). Earnings for Rigel Pharmaceuticals are expected to grow in the coming year, from ($0.52) to ($0.33) per share. Rigel Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 1st, 2022 based off prior year's report dates.

Rigel Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/1/2022
(Estimated)
        
8/2/2022Q2 2022($0.12)($0.08)+$0.04($0.08)$23.56 million$29.82 million
5/3/2022Q1 2022($0.12)($0.16)($0.04)($0.16)$18.49 million$16.74 million    
3/1/2022Q4 2021($0.13)($0.13)($0.13)$21.20 million$20.41 million    
11/2/20219/30/2021($0.10)($0.12)($0.02)($0.12)$24.16 million$21.54 million    
8/3/20216/30/2021($0.11)($0.08)+$0.03($0.08)$22.08 million$26.27 million    
5/5/20213/31/2021$0.01$0.22+$0.21$0.22$40.06 million$81.02 million  
3/1/202112/31/2020($0.11)($0.11)($0.11)$18.37 million$18.45 million  
11/5/20209/30/2020($0.12)($0.08)+$0.04($0.08)$17.60 million$18.39 million  
8/4/20206/30/2020($0.13)($0.10)+$0.03($0.10)$14.28 million$16.02 million  
5/5/20203/31/2020$0.13$0.13$0.13$56.94 million$55.76 million  
2/27/202012/31/2019($0.08)($0.10)($0.02)($0.10)$15.78 million$15.40 million  
11/5/2019Q3 19($0.11)($0.07)+$0.04($0.07)$16.27 million$20.86 million  
8/6/2019Q2 19($0.14)($0.12)+$0.02($0.12)$9.25 million$10.41 million
5/7/2019Q1($0.13)($0.11)+$0.02($0.11)$12.00 million$12.62 million
2/28/2019Q4 2018$0.03$0.02($0.01)$0.02$36.59 million$37.86 million
11/6/2018Q3($0.16)($0.14)+$0.02($0.14)$3.52 million$4.87 million  
8/8/2018Q2 2018($0.16)($0.16)($0.16)$0.30 million$1.79 million
5/1/2018Q1 2018($0.17)($0.17)($0.17)$0.20 million  
3/6/2018Q4 2017($0.13)($0.18)($0.05)($0.18)$0.05 million  
11/7/2017Q3 2017($0.15)($0.14)+$0.01($0.14)$0.90 million
8/1/2017Q2 2017($0.15)($0.16)($0.01)($0.16)$2.05 million  
5/2/2017Q1 2017($0.12)($0.13)($0.01)($0.13)$4.30 million$3.58 million  
3/7/2017Q4 2016($0.21)($0.16)+$0.05($0.16)$4.25 million$3.00 million  
11/1/2016Q3 2016($0.24)($0.24)($0.24)$3.97 million$3.76 million  
8/2/2016Q2 2016($0.20)($0.15)+$0.05($0.15)$3.75 million$8.60 million
5/3/2016Q1 2016($0.17)($0.19)($0.02)($0.19)$4.00 million$5.03 million  
3/8/2016Q4 2015($0.18)($0.14)+$0.04($0.14)$8.90 million$8.50 million  
11/3/2015Q3 2015($0.17)($0.08)+$0.09($0.08)$5.00 million$12.90 million  
8/4/2015Q2 2015($0.20)($0.16)+$0.04($0.16)$2.67 million$5.18 million  
5/7/2015Q1 2015($0.21)($0.21)($0.21)$16.00 million$2.18 million  
3/3/2015Q4 2014($0.25)($0.25)($0.25)$2.50 million$8.25 million
11/4/2014Q3 2014($0.29)($0.24)+$0.05($0.24)$1.70 million
8/5/2014Q2 2014($0.25)($0.29)($0.04)($0.29)$1.05 million
5/7/2014Q1 2014($0.26)($0.25)+$0.01($0.25)$0.43 million
3/4/2014Q4 2013($0.24)($0.19)+$0.05($0.19)$5.80 million
11/5/2013Q3 2013($0.29)($0.25)+$0.04($0.23)$260.00 million  
8/6/2013Q2 2013($0.31)($0.26)+$0.05($0.26)$0.53 million$1.40 million
5/7/2013Q1 2013($0.32)($0.29)+$0.03($0.29)$1.73 million  
3/5/2013Q4 2012($0.32)($0.30)+$0.02  
11/6/2012Q312($0.38)($0.36)+$0.02$0.84 million
8/7/2012($0.34)($0.35)($0.01)
5/1/2012($0.33)($0.32)+$0.01  
3/6/2012($0.28)($0.36)($0.08)
11/1/2011($0.28)($0.25)+$0.03  
8/2/2011($0.36)($0.37)($0.01)
5/3/2011($0.36)($0.40)($0.04)
3/1/2011Q4 2010($0.36)($0.33)+$0.03($0.33)
11/2/2010Q3 2010$0.58$0.96+$0.38$0.96
8/3/2010Q2 2010$0.45$0.52+$0.07$0.52
5/4/2010Q1 2010($0.06)($0.43)($0.37)($0.43)
3/2/2010Q4 2009($0.45)($0.48)($0.03)($0.48)
11/3/2009Q3 2009($0.56)($0.70)($0.14)($0.70)
8/4/2009Q2 2009($0.80)($0.81)($0.01)($0.81)
5/5/2009Q1 2009($0.97)($0.80)+$0.17($0.78)
2/24/2009Q4 2008($0.96)($0.91)+$0.05($0.91)
11/3/2008Q3 2008($0.75)($1.03)($0.28)($1.03)
8/5/2008Q2 2008($0.66)($0.93)($0.27)($0.93)
5/6/2008Q1 2008($0.58)($0.79)($0.21)($0.79)
2/12/2008Q4 2007($0.44)($0.61)($0.17)($0.61)












Rigel Pharmaceuticals Earnings - Frequently Asked Questions

When is Rigel Pharmaceuticals's earnings date?

Rigel Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 1st, 2022 based off last year's report dates. Learn more on RIGL's earnings history.

Did Rigel Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Rigel Pharmaceuticals (NASDAQ:RIGL) reported ($0.08) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.12) by $0.04. Learn more on analysts' earnings estimate vs. RIGL's actual earnings.

How much revenue does Rigel Pharmaceuticals generate each year?

Rigel Pharmaceuticals (NASDAQ:RIGL) has a recorded annual revenue of $149.24 million.

How much profit does Rigel Pharmaceuticals generate each year?

Rigel Pharmaceuticals (NASDAQ:RIGL) has a recorded net income of -$17.91 million. RIGL has generated -$0.49 earnings per share over the last four quarters.

What is Rigel Pharmaceuticals's EPS forecast for next year?

Rigel Pharmaceuticals's earnings are expected to grow from ($0.52) per share to ($0.33) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:RIGL) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.